Clinical trials: Hemodialysis
Anemia in End Stage Renal Disease
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
The purpose of this study is to evaluate the efficacy and safety of FG-4592 in maintaining and/or correcting hemoglobin (Hb) given to subjects with End Stage Renal Disease (ESRD) on maintenance hemodialysis and receiving epoetin…
- Trial name
- NCT01596855
- Testing
- FG-4592, Epoetin Alfa
- Where
- 9 sites in China
- Volunteers
- 96 people
- Sponsor
- Kyntra Bio
Pruritus
A Study of SHR4010 in Patients With Hemodialysis
The study is being conducted to evaluate the safety and pharmacokinetics of SHR0410 in patients with hemodialysis.
- Trial name
- NCT04099927
- Testing
- SHR0410
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chronic Kidney Disease Stage V, Hemodialysis
Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients
This study was designed to evaluate the effectiveness, safety, and impact on quality of life when paricalcitol (Zemplar® intravenous [IV]) is administered in Venezuelan patients on hemodialysis who are at risk of developing…
- Trial name
- NCT01758289
- Where
- 8 sites in Venezuela
- Volunteers
- 105 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End Stage Renal Disease
A Safety Study of Pentoxifylline for the Treatment of Anemia
Chronic kidney disease (CKD) patients have increased levels of inflammation and oxidative stress, which in turn contribute to anemia and cardiovascular disease.
- Trial name
- NCT01102218
- Testing
- Erythropoietin, Pentoxifylline
- Where
- 10 sites in United States
- Volunteers
- 48 people
- Sponsor
- Fresenius Medical Care North America
Hemodialysis Patients
Clinical Study of R744 to Hemodialysis Patients
This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.
- Trial name
- NCT00491868
- Testing
- R744, rHuEPO
- Where
- 5 sites in Japan
- Volunteers
- 134 people
- Sponsor
- Chugai Pharmaceutical
HIV Infections, Kidney Failure, Chronic
Retrovir Capsules in the Treatment of HIV-Infected Patients in Renal Failure
To evaluate the safety, tolerance, and pharmacokinetics of Retrovir (AZT) administration in HIV-infected patients in renal failure receiving maintenance hemodialysis.
- Trial name
- NCT00002047
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
Secondary Hyperparathyroidism
SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
To evaluate the safety and efficacy of treatment with SK-1403 for 52 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
- Trial name
- NCT03626948
- Testing
- SK-1403
- Where
- Japan
- Volunteers
- 157 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Hyperphosphatemia
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients
To evaluate the effect and safety of KHK7791 in combination with phosphate binders to treat Hyperphosphatemia in ptatients on HD.
- Trial name
- NCT03864445
- Testing
- KHK7791, Placebp
- Where
- Japan
- Volunteers
- 47 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This study is a randomized study designed as a 2x2 cross-over in two periods (Period 1 and Period 2) to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of EOS789 in patients with chronic kidney…
- Trial name
- NCT02965053
- Testing
- EOS789, Renvela
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Chugai Pharmaceutical
Anemia
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
This trial will be conducted to demonstrate the efficacy and safety of vadadustat compared to darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants after conversion from current…
- Trial name
- NCT04313153
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 59 sites in United States, Czechia and 4 more
- Volunteers
- 319 people
- Sponsor
- Akebia Therapeutics
Anemia, Chronic Kidney Disease
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
This study will evaluate the efficacy and safety of intravenous MK2578, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving erythropoietin stimulating…
- Trial name
- NCT00924781
- Testing
- MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline, MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
End Stage Renal Disease
A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis
Malnutrition and altered protein catabolism are serious problems in renal failure and hemodialysis (HD) patients. The purpose of this study is to characterize the safety of GHRP-1/AG in subjects with ESRD on HD; to characterize…
- Trial name
- NCT00381602
- Testing
- GHRP-1/AG 70 mg depot in ESRD
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- QLT Inc.
Hyperphosphatemia
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in…
- Trial name
- NCT04766398
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 169 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013…
- Trial name
- NCT06976177
- Testing
- MT1013
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
End Stage Renal Disease
An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System
This study is designed to monitor and assess the safety of continued access to the HemoCare™ Hemodialysis System used during the review of the pre-market notifications for the devices in the HemoCare™ Hemodialysis System.
- Trial name
- NCT04198012
- Testing
- HemoCare™ Hemodialysis System
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Deka Research and Development
Renal Impairment
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring…
- Trial name
- NCT07217886
- Testing
- S-892216-PO
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Shionogi
Dialysis, Chronic Renal Failure
A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System
The study objective is to verify the safety and effectiveness of the DBB-EXA ES Hemodialysis Delivery System to consistently deliver dialysate of the appropriate quality for infusion.
- Trial name
- HEMO (NCT04655989)
- Testing
- DBB-EXA ES Hemodialysis System
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Nikkiso America, Inc.
Chronic Kidney Disease, End-stage Renal Disease
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring…
- Conditions
- Chronic Kidney Disease, End-stage Renal Disease, Anaemia
- Trial name
- MONITOR-CKD5 (NCT01121237)
- Testing
- Recombinant human erythropoietin alfa (biosimilar)
- Where
- 95 sites in Austria, France and 8 more
- Volunteers
- 2,086 people
- Sponsor
- Sandoz
Renal Failure, Cardiovascular Diseases
HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life Assessed by MRI Scanning
The purpose of this study is to characterise in detail cardiac, cerebral and renal structure, function and perfusion in patients on haemodialysis (HD) using magnetic imaging techniques.
- Conditions
- Renal Failure, Cardiovascular Diseases, Congenital Disorders
- Trial name
- HD-REMODEL (NCT03280901)
- Testing
- HD, Magnetic Resonance Imaging (MRI) scans
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hyperplasia, Chronic Renal Failure
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed…
- Trial name
- NCT00086164
- Testing
- edifoligide (E2F Decoy)
- Where
- 21 sites in United States
- Sponsor
- Anesiva, Inc.